What does NICE say about energy devices and sexual function symptoms?
NICE (National Institute for Health and Care Excellence) has issued specific guidance on vaginal energy-based devices, primarily through interventional procedure guidance IPG615 (2018). NICE states that current evidence on the efficacy of these devices for vaginal atrophy is limited in quality and quantity, and recommends they should only be used with special arrangements for clinical governance, consent, and audit. The technology remains under review, particularly for women who cannot or will not use hormonal therapy.
Show Detailed Answer
Energy-based devices—including fractional CO₂ lasers and radiofrequency platforms—have been marketed for treating vaginal atrophy, dryness, laxity, and associated sexual function symptoms such as pain with intercourse (dyspareunia) and reduced sensation. These devices deliver controlled thermal energy to vaginal tissue with the aim of stimulating collagen remodelling, improving tissue thickness, elasticity, and lubrication.
However, the regulatory and clinical landscape is complex. NICE does not currently endorse these devices as a first-line or routine treatment, and their position reflects concerns about the strength of published evidence, the need for longer-term safety data, and the absence of large-scale randomised controlled trials comparing energy devices to established treatments like topical oestrogen.
NICE Interventional Procedure Guidance IPG615
Published in February 2018, IPG615 addresses “microwave treatment for severe menopausal symptoms.” NICE has also commented on laser and radiofrequency treatments under its broader interventional procedures framework. The key points include:
- Limited Evidence: NICE found that current evidence on efficacy is “limited in quantity and quality.” Most published studies are small, short-term, and lack control groups or sham comparisons.
- Safety Profile: The safety profile appears acceptable in the short term, with most adverse events being mild (temporary discomfort, discharge, or spotting). However, long-term safety data—particularly on tissue changes over years—are not yet available.
- Special Arrangements: NICE recommends these treatments should only be offered with “special arrangements for clinical governance, consent, and audit.” This means clinics must have robust protocols for patient selection, informed consent (explaining uncertainty), and systematic follow-up to contribute to the evidence base.
- Patient Selection: The guidance suggests energy devices may be considered for women who cannot use oestrogen (due to contraindications such as hormone-sensitive cancers) or who decline it after full counselling.
NICE Menopause Guidance (NG23)
NICE guideline NG23 (updated 2024) on menopause diagnosis and management prioritises topical vaginal oestrogen as the first-line treatment for genitourinary syndrome of menopause (GSM), which includes vaginal dryness, dyspareunia, and urinary symptoms. Energy devices are not mentioned as a recommended option within this pathway, reinforcing that they remain an “emerging” rather than established therapy.
What Does This Mean for Patients?
If you are considering an energy-based device for vaginal atrophy or sexual function symptoms, NICE’s position means:
- The treatment is not considered “routine” or “standard of care” in the UK.
- Your clinician should discuss all established options first (topical oestrogen, lubricants, pelvic physiotherapy).
- You should be fully informed that evidence is still evolving, and that your outcomes will ideally be monitored and reported to contribute to safety and efficacy data.
- The treatment may be offered in specialist private clinics with appropriate governance, but is unlikely to be available through standard NHS pathways unless part of a research study.
Common Concerns & Myths
“Does NICE saying evidence is limited mean the devices don’t work?”
Not necessarily. It means the current research base is not yet robust enough to make a definitive recommendation. Some women do report improvements in symptoms, but we need larger, longer trials to understand who benefits most and whether effects are sustained.
“If I can’t use oestrogen, is this my only option?”
No. Non-hormonal moisturisers, lubricants, vaginal DHEA (prasterone), and pelvic physiotherapy are all evidence-based alternatives that can be used alongside or instead of energy devices.
“Will the NHS fund this treatment?”
Currently, it is highly unlikely. Energy-based vaginal treatments are typically offered in private specialist clinics. Always ask about total costs, number of sessions required, and what follow-up is included.
Clinical Context
Energy-based vaginal rejuvenation emerged as a potential treatment for women experiencing vaginal atrophy—often due to menopause, breastfeeding, or cancer treatment—who seek non-hormonal options. The devices aim to heat the deeper layers of vaginal tissue to trigger collagen production and improve tissue structure. While patient-reported outcomes in early studies have been encouraging, regulatory bodies including NICE and the FDA have called for caution, emphasising the need for rigorous clinical trials and long-term safety monitoring before these treatments can be recommended as standard care. Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Self-Care & Lifestyle
Before considering device-based treatments, ensure you have optimised conservative measures:
- Vaginal Moisturisers: Use regularly (not just before sex) to maintain tissue hydration. Look for hyaluronic acid-based products.
- Lubricants: Water-based or silicone-based lubricants during intimacy reduce friction and discomfort.
- Pelvic Floor Health: Engage in pelvic floor physiotherapy if you have muscle tension or pain, which can worsen sexual function symptoms.
- Systemic Health: Manage cardiovascular health, blood sugar, and stress, all of which affect tissue perfusion and nerve sensitivity.
Medical & Specialist Options
If conservative measures are insufficient, discuss these evidence-based medical options with your GP or gynaecologist:
- Topical Vaginal Oestrogen: The gold standard for treating GSM. Available as creams, pessaries, or slow-release rings. Safe even for most women with a history of breast cancer (discuss with your oncology team).
- Vaginal DHEA (Prasterone): A non-oestrogen hormonal option licensed for postmenopausal vaginal atrophy in some countries.
- Systemic HRT: May improve vaginal symptoms in perimenopausal women, though local oestrogen is often still needed.
- Energy Devices (Laser/RF): May be considered in specialist settings for women who cannot or will not use hormones, with full informed consent and follow-up as per NICE IPG615.
For a holistic assessment and personalised treatment pathway, you can meet the clinical team or book a consultation to discuss your options in detail.
C. Red Flags (When to see a GP)
Seek urgent medical review if you experience unexpected vaginal bleeding (especially post-menopause), severe pain, signs of infection, or any new lumps or ulcers. These require clinical examination and investigation before any elective treatment.
External Resources:
Educational only. Results vary. Not a cure.
Regulatory Status: NICE is cautious about vaginal energy devices. Current guidelines (IPG696 & IPG697) classify the evidence for long-term safety as "inadequate," recommending they be used with strict "Clinical Governance" (audit) only after standard treatments like Physio or Estrogen have failed.
Additional Regulatory Details
In the UK, NICE (National Institute for Health and Care Excellence) separates "Cosmetic" marketing from "Medical" reality. There are two specific guidance documents you should check:
IPG696: For Stress Urinary Incontinence
- Status: "Evidence on long-term safety and efficacy is inadequate."
- The Rule: This procedure should generally be used in the context of research or with special arrangements for clinical governance (meaning your clinic must audit your results and report complications).
IPG697: For Vaginal Atrophy (Dryness/GSM)
- Status: Short-term safety is good, but long-term efficacy is still being established.
- The Rule: It should not be the first option offered. It is intended for women who cannot take or have not responded to vaginal estrogen.
NICE and the British Menopause Society (BMS) are clear: Energy devices are not first-line treatments. A reputable clinic will require you to try standard medical therapies first.
- Step 1 (First Line): Lifestyle changes (weight loss, smoking cessation) and Pelvic Floor Physiotherapy (for leaks).
- Step 2 (Medical): Topical Estrogen (creams/pessaries) and non-hormonal moisturisers for dryness. This is the "Gold Standard".
- Step 3 (Interventional): Laser or RF is considered only if Step 1 and 2 fail, or if you are medically unable to use hormones (e.g., certain breast cancer survivors).
To comply with NICE governance, your consent form must explicitly state:
- That evidence for long-term results (>12 months) is limited.
- That some studies suggest the benefit may be similar to placebo ("sham" treatment) for some women.
- That you are aware standard medical alternatives (like Estrogen) exist.